These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 35452835)

  • 21. The association of CYP2D6 gene polymorphisms in the full-length coding region with higher recurrence rate of vivax malaria in Yunnan Province, China.
    Huang H; Dong Y; Xu Y; Deng Y; Zhang C; Liu S; Chen M; Liu Y
    Malar J; 2021 Mar; 20(1):160. PubMed ID: 33743705
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses.
    Silvino AC; Costa GL; Araújo FC; Ascher DB; Pires DE; Fontes CJ; Carvalho LH; Brito CF; Sousa TN
    PLoS One; 2016; 11(7):e0160172. PubMed ID: 27467145
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cytochrome P450 2D6 (CYP2D6) and glucose-6-phosphate dehydrogenase (G6PD) genetic variations in Thai vivax malaria patients: Implications for 8-aminoquinoline radical cure.
    Chamchoy K; Sudsumrit S; Thita T; Krudsood S; Patrapuvich R; Boonyuen U
    PLoS Negl Trop Dis; 2022 Dec; 16(12):e0010986. PubMed ID: 36508454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria.
    Bennett JW; Pybus BS; Yadava A; Tosh D; Sousa JC; McCarthy WF; Deye G; Melendez V; Ockenhouse CF
    N Engl J Med; 2013 Oct; 369(14):1381-2. PubMed ID: 24088113
    [No Abstract]   [Full Text] [Related]  

  • 25. Safety and efficacy of primaquine in patients with
    Verma R; Commons RJ; Gupta A; Rahi M; Nitika ; Bharti PK; Thriemer K; Rajasekhar M; Singh-Phulgenda S; Adhikari B; Alam MS; Ghimire P; Khan WA; Kumar R; Leslie T; Ley B; Llanos-Cuentas A; Pukrittayakamee S; Rijal KR; Rowland M; Saravu K; Simpson JA; Guerin PJ; Price RN; Sharma A
    BMJ Glob Health; 2023 Dec; 8(12):. PubMed ID: 38123228
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primaquine treatment and relapse in Plasmodium vivax malaria.
    Rishikesh K; Saravu K
    Pathog Glob Health; 2016; 110(1):1-8. PubMed ID: 27077309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
    Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
    Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose adjustment of paroxetine based on CYP2D6 activity score inferred metabolizer status in Chinese Han patients with depressive or anxiety disorders: a prospective study and cross-ethnic meta-analysis.
    Liao Y; Sun Y; Guo J; Kang Z; Sun Y; Zhang Y; He J; Huang C; Sun X; Zhang JM; Wang J; Wang HN; Chen ZY; Wang K; Pan J; Ni AH; Weng S; Wang A; Cao C; Sun L; Zhang Y; Kuang L; Zhang Y; Liu Z; Yue W;
    EBioMedicine; 2024 Jun; 104():105165. PubMed ID: 38776596
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
    Mehdipour P; Rajasekhar M; Dini S; Zaloumis S; Abreha T; Adam I; Awab GR; Baird JK; Brasil LW; Chu CS; Cui L; Daher A; do Socorro M Gomes M; Gonzalez-Ceron L; Hwang J; Karunajeewa H; Lacerda MVG; Ladeia-Andrade S; Leslie T; Ley B; Lidia K; Llanos-Cuentas A; Longley RJ; Monteiro WM; Pereira DB; Rijal KR; Saravu K; Sutanto I; Taylor WRJ; Thanh PV; Thriemer K; Vieira JLF; White NJ; Zuluaga-Idarraga LM; Guerin PJ; Price RN; Simpson JA; Commons RJ;
    Malar J; 2023 Oct; 22(1):306. PubMed ID: 37817240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular and immunological analyses of confirmed Plasmodium vivax relapse episodes.
    Maneerattanasak S; Gosi P; Krudsood S; Chimma P; Tongshoob J; Mahakunkijcharoen Y; Sukasem C; Imwong M; Snounou G; Khusmith S
    Malar J; 2017 May; 16(1):228. PubMed ID: 28558712
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics/pharmacodynamics of chloroquine and artemisinin-based combination therapy with primaquine.
    Daher A; Aljayyoussi G; Pereira D; Lacerda MVG; Alexandre MAA; Nascimento CT; Alves JC; da Fonseca LB; da Silva DMD; Pinto DP; Rodrigues DF; Silvino ACR; de Sousa TN; de Brito CFA; Ter Kuile FO; Lalloo DG
    Malar J; 2019 Sep; 18(1):325. PubMed ID: 31547827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Case Report: Primaquine Failure for Radical Cure of
    Teklehaimanot A; Teklehaimanot H; Girmay A; Woyessa A
    Am J Trop Med Hyg; 2020 Jul; 103(1):415-420. PubMed ID: 32394882
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Increased primaquine total dose prevents Plasmodium vivax relapses in patients with impaired CYP2D6 activity: report of three cases.
    de Pina-Costa A; Silvino ACR; Dos Santos EM; Pedro RS; Moreira J; Umana GL; da Silva ADT; da Rosa Santos OHL; de Deus Henriques KM; Daniel-Ribeiro CT; Brasil P; Sousa TN; Siqueira AM
    Malar J; 2021 Aug; 20(1):341. PubMed ID: 34391426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single dose tafenoquine for preventing relapse in people with plasmodium vivax malaria-an updated meta-analysis.
    Anjum MU; Naveed AK; Mahmood SN; Naveed OK
    Travel Med Infect Dis; 2020; 36():101576. PubMed ID: 32036012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Plasmodium vivax malaria and antimalarial treatment on cytochrome P450 activity in Brazilian patients.
    Almeida AC; Elias ABR; Marques MP; de Melo GC; da Costa AG; Figueiredo EFG; Brasil LW; Rodrigues-Soares F; Monteiro WM; de Lacerda MVG; Lanchote VL; Suarez-Kurtz G
    Br J Clin Pharmacol; 2021 Apr; 87(4):1859-1868. PubMed ID: 32997351
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A clinical tool to predict Plasmodium vivax recurrence in Malaysia.
    Mat Ariffin N; Islahudin F; Kumolosasi E; Makmor-Bakry M
    BMC Infect Dis; 2017 Dec; 17(1):759. PubMed ID: 29216842
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of Cytochrome P450 Isoenzyme 2D6 (CYP2D6) Genotypes and Pharmacogenomic Impact on Primaquine Metabolism in an Active-Duty US Military Population.
    Spring MD; Sousa JC; Li Q; Darko CA; Morrison MN; Marcsisin SR; Mills KT; Potter BM; Paolino KM; Twomey PS; Moon JE; Tosh DM; Cicatelli SB; Froude JW; Pybus BS; Oliver TG; McCarthy WF; Waters NC; Smith PL; Reichard GA; Bennett JW
    J Infect Dis; 2019 Oct; 220(11):1761-1770. PubMed ID: 31549155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction of the CYP2D6 enzymatic activity based on investigating of the CYP2D6 genotypes around the vivax malaria patients in Yunnan Province, China.
    Dong Y; Huang H; Deng Y; Xu Y; Chen M; Liu Y; Zhang C
    Malar J; 2021 Nov; 20(1):448. PubMed ID: 34823523
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Relapse of Plasmodium vivax and Plasmodium ovale Malaria With and Without Primaquine Treatment in a Nonendemic Area.
    Wångdahl A; Sondén K; Wyss K; Stenström C; Björklund D; Zhang J; Hervius Askling H; Carlander C; Hellgren U; Färnert A
    Clin Infect Dis; 2022 Apr; 74(7):1199-1207. PubMed ID: 34216464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic analysis of primaquine tolerance in a patient with relapsing vivax malaria.
    Bright AT; Alenazi T; Shokoples S; Tarning J; Paganotti GM; White NJ; Houston S; Winzeler EA; Yanow SK
    Emerg Infect Dis; 2013 May; 19(5):802-5. PubMed ID: 23648098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.